Therapeutic effect of rosuvastatin combined clopidogrel bisulfate on patients with coronary heart disease
10.3969/j.issn.1008-0074.2017.04.25
- VernacularTitle:瑞舒伐他汀联合硫酸氢氯吡格雷对冠心病患者的临床疗效
- Author:
Xiaoming LUO
;
Jianjie ZOU
;
Bochao ZHANG
;
Zhenglong ZHONG
- Keywords:
Coronary disease;
Rosuvastatin;
Clopidogrel
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2017;26(4):441-444
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore therapeutic effect of rosuvastatin combined clopidogrel bisulfate tablet on patients with coronary heart disease (CHD).Methods: A total of 124 patients, who were diagnosed as CHD by coronary angiography, were selected, randomly and equally divided into routine treatment group (received routine treatment,including clopidogrel bisulfate tablet) and combined treatment group (received rosuvastatin based on routine treatment group), both groups were treated for six months.Cardiac function, serum levels of angiotensin II (Ang II), vascular endothelial growth factor (VEGF) and nitric oxide (NO), and therapeutic effect were measured and compared between two groups before and after treatment.Results: Total effective rate of combined treatment group was significantly higher than that of routine treatment group (96.77% vs.83.87%, P=0.015).Compared with routine treatment group after treatment, there were significant rise in left ventricular ejection fraction [(61.89±7.02)% vs.(68.96±8.23)%] and NO level [(75.25±9.45) μmol/L vs.(82.25±10.22) μmol/L], and significant reductions in wall motion score index [(1.35±0.39)% vs.(1.11±0.29)%], levels of Ang Ⅱ [(102.25±6.93) ng/L vs.(52.99±5.36) ng/L] and VEGF [(328.25±23.41) ng/L vs.(228.69±22.69) ng/L] in combined treatment group, P<0.01 all.Conclusion: Rosuvastatin combined clopidogrel bisulfate tablet can effectively improve heart function, serum levels of Ang II, VEGF and NO in patients with coronary heart disease, the therapeutic effect is significant, which is worth extending.
